Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis
Ankle Brachial Index Collaboration, F G R Fowkes, G D Murray, I Butcher, C L Heald, R J Lee, L E Chambless, A R Folsom, A T Hirsch, M Dramaix, G deBacker, J-C Wautrecht, M Kornitzer, A B Newman, M Cushman, K Sutton-Tyrrell, F G R Fowkes, A J Lee, J F Price, R B d'Agostino, J M Murabito, P E Norman, K Jamrozik, J D Curb, K H Masaki, B L Rodríguez, J M Dekker, L M Bouter, R J Heine, G Nijpels, C D A Stehouwer, L Ferrucci, M M McDermott, H E Stoffers, J D Hooi, J A Knottnerus, M Ogren, B Hedblad, J C Witteman, M M B Breteler, M G M Hunink, A Hofman, M H Criqui, R D Langer, A Fronek, W R Hiatt, R Hamman, H E Resnick, J Guralnik, M M McDermott, Ankle Brachial Index Collaboration, F G R Fowkes, G D Murray, I Butcher, C L Heald, R J Lee, L E Chambless, A R Folsom, A T Hirsch, M Dramaix, G deBacker, J-C Wautrecht, M Kornitzer, A B Newman, M Cushman, K Sutton-Tyrrell, F G R Fowkes, A J Lee, J F Price, R B d'Agostino, J M Murabito, P E Norman, K Jamrozik, J D Curb, K H Masaki, B L Rodríguez, J M Dekker, L M Bouter, R J Heine, G Nijpels, C D A Stehouwer, L Ferrucci, M M McDermott, H E Stoffers, J D Hooi, J A Knottnerus, M Ogren, B Hedblad, J C Witteman, M M B Breteler, M G M Hunink, A Hofman, M H Criqui, R D Langer, A Fronek, W R Hiatt, R Hamman, H E Resnick, J Guralnik, M M McDermott
Abstract
Context: Prediction models to identify healthy individuals at high risk of cardiovascular disease have limited accuracy. A low ankle brachial index (ABI) is an indicator of atherosclerosis and has the potential to improve prediction.
Objective: To determine if the ABI provides information on the risk of cardiovascular events and mortality independently of the Framingham risk score (FRS) and can improve risk prediction.
Data sources: Relevant studies were identified. A search of MEDLINE (1950 to February 2008) and EMBASE (1980 to February 2008) was conducted using common text words for the term ankle brachial index combined with text words and Medical Subject Headings to capture prospective cohort designs. Review of reference lists and conference proceedings, and correspondence with experts was conducted to identify additional published and unpublished studies.
Study selection: Studies were included if participants were derived from a general population, ABI was measured at baseline, and individuals were followed up to detect total and cardiovascular mortality.
Data extraction: Prespecified data on individuals in each selected study were extracted into a combined data set and an individual participant data meta-analysis was conducted on individuals who had no previous history of coronary heart disease.
Results: Sixteen population cohort studies fulfilling the inclusion criteria were included. During 480,325 person-years of follow-up of 24,955 men and 23,339 women, the risk of death by ABI had a reverse J-shaped distribution with a normal (low risk) ABI of 1.11 to 1.40. The 10-year cardiovascular mortality in men with a low ABI (< or = 0.90) was 18.7% (95% confidence interval [CI], 13.3%-24.1%) and with normal ABI (1.11-1.40) was 4.4% (95% CI, 3.2%-5.7%) (hazard ratio [HR], 4.2; 95% CI, 3.3-5.4). Corresponding mortalities in women were 12.6% (95% CI, 6.2%-19.0%) and 4.1% (95% CI, 2.2%-6.1%) (HR, 3.5; 95% CI, 2.4-5.1). The HRs remained elevated after adjusting for FRS (2.9 [95% CI, 2.3-3.7] for men vs 3.0 [95% CI, 2.0-4.4] for women). A low ABI (< or = 0.90) was associated with approximately twice the 10-year total mortality, cardiovascular mortality, and major coronary event rate compared with the overall rate in each FRS category. Inclusion of the ABI in cardiovascular risk stratification using the FRS would result in reclassification of the risk category and modification of treatment recommendations in approximately 19% of men and 36% of women.
Conclusion: Measurement of the ABI may improve the accuracy of cardiovascular risk prediction beyond the FRS.
Conflict of interest statement
Disclosures: Several authors have received honoraria, consulting fees or research grants from Sanofi Aventis/BMS for purposes other than this research. In addition Dr McDermott has received consulting fees from Hutchison Technology and educational honoraria from Otsuka Pharmaceuticals, and Dr Ogren is an employee of AstraZeneca R + D. Otherwise, the authors have no potential conflict of interest, including special financial interests and relationships and affiliations, relevant to the subject of this manuscript.
Figures
Source: PubMed